Trial Profile
A Phase II/III, Multicenter, Partially Randomized, Open Label Trial Investigating Safety and Efficacy of On-demand and Prophylactic Treatment With BAY94-9027 in Severe Hemophilia A
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Damoctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
- Acronyms PROTECT VIII extension; PROTECT-VIII
- Sponsors Bayer; Bayer HealthCare
- 31 Oct 2023 According to Octapharma media release, data from the study were presented in the European Journal of Haematology.
- 31 Oct 2023 Results of Indirect comparison from a matching-adjusted indirect comparison (MAIC) of Nuwiq (simoctocog alfa) versus extended half-life recombinant factor VIII (rFVIII) concentrates in haemophilia A patients undergoing personalised prophylaxis published in the Media Release
- 13 Dec 2022 Results comparing the efficacy of personalized prophylaxis with simoctocog alfa with three comparator FVIII products - efmoroctocog alfa, damoctocog alfa pegol and rurioctocog alfa pegol in the patients from NuPreviq, A-LONG, PROTECT VIII and PROPEL studies presented at the 64th American Society of Hematology Annual Meeting and Exposition.